"O IPO de Coimbra, tem a missão de desenvolver ações nos domínios da prestação de cuidados de saúde"

During the past decade, IPO de Coimbra; Servico de Oncologia Medica conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 7 clinical trials were completed, i.e. on average, 41.2% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 5 clinical trials were completed. i.e. 45.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IPO de Coimbra; Servico de Oncologia Medica" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Pfizer" with 2 trials sponsored, "Bayer" with 1 trials sponsored, "BioNTech SE" with 1 trials sponsored and "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IPO de Coimbra; Servico de Oncologia Medica" #1 collaborator was "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "Eisai Inc." with 1 trials as a collaborator, "GORTEC (Head and Neck Oncology and Radiotherapy Group)" with 1 trials as a collaborator, "Helsinn Healthcare SA" with 1 trials as a collaborator and "Instituto Português Oncologia de Coimbra Francisco Gentil E. P. E." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "IPO de Coimbra; Servico de Oncologia Medica" are "Breast Cancer" (3 trials), "Glioblastoma" (2 trials), "Squamous Cell Carcinoma of the Head and Neck" (2 trials), "Advanced Cholangiocarcinoma" (1 trials) and "Breast Neoplasms" (1 trials). Many other conditions were trialed in "IPO de Coimbra; Servico de Oncologia Medica" in a lesser frequency.

Most popular intervention types in "IPO de Coimbra; Servico de Oncologia Medica" are "Drug" (20 trials), "Radiation" (3 trials), "Biological" (2 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Atezolizumab" (3 trials), "Avelumab" (2 trials), "Bevacizumab" (2 trials) and "Cisplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "IPO de Coimbra; Servico de Oncologia Medica" are 23 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "IPO de Coimbra; Servico de Oncologia Medica". undefined are not yet recruiting, 2 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in IPO de Coimbra; Servico de Oncologia Medica, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in IPO de Coimbra; Servico de Oncologia Medica, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".